|
Monday April 26, 2010
| 7.30 a.m. |
Continental Breakfast |
| |
Registration |
| |
|
| 8.30 a.m. |
Welcome & Introduction |
| |
Peter R. Byron, Ph.D.
Professor, School of Pharmacy, Virginia Commonwealth University. |
| |
|
| |
Presentation of Charles G. Thiel Award |
| |
|
| 9.00 a.m. |
PLENARY LECTURE |
| |
|
| |
Sponsors: ‘Our Platinum Sponsors’
Moderator: Peter R. Byron, Ph.D. |
| |
|
| |
Pulmonary Hypertension, Etiology and Pathogenesis: New Treatments and Targets.
Norbert F. Voelkel, M.D.,
Director, Victoria Johnson Center for Obstructive Lung Diseases, Virginia Commonwealth University, Richmond, VA. |
| |
|
| 10.00 a.m. |
Refreshments |
| |
|
| SESSION 1: |
Modulating Systemic Drug Delivery via the Lung |
| |
|
| |
Sponsor: Vectura
Moderator: Igor Gonda, Ph.D. |
| |
|
| 10.30 a.m. |
The Staccato System: Inhaler Design Characteristics for Rapid Treatment of CNS Disorders.
Peter D. Noymer, Ph.D.,
Alexza Pharmaceuticals, Mountain View, CA. |
| |
|
| 11.00 a.m. |
Contrasting Pharmacokinetics and Pharmacodynamics of Afrezza® and Exubera®.
Robert A. Baughman, Pharm.D., Ph.D.,
MannKind Corporation, Danbury, CT. |
| |
|
| 11.30 a.m. |
Beyond Insulin: The Shrinking Pulmonary Delivery Window for Systemic Biotech Drugs.
Masahiro Sakagami, Ph.D.,
Virginia Commonwealth University, Richmond, VA. |
| |
|
| 12.00 noon |
Lunchtime |
| |
|
11.30 a.m.
- 2.30 p.m. |
Scientific Poster Session & Technology Exhibition |
| |
Sponsor: Copley Scientific
Moderator: Richard N. Dalby, Ph.D. |
| |
|
| SESSION 2: |
Infections and Cancer: Enhancing Host Defenses |
| |
|
| |
Sponsor: Next Breath
Moderator: John S. Patton, Ph.D. |
| |
|
| 2.00 p.m. |
Aerosol Cytokines and Chemotherapy of Cancer: Practical Considerations and Experience.
Peter M. Anderson, M.D. Ph.D.,
University of Texas MD Anderson Cancer Center, Houston, Texas. |
| |
|
| 2.30 p.m. |
Pulmonary Vaccination: Dendritic Cells and other Antigen Presenters in the Lung.
Christophe von Garnier, M.D.,
Bern University, Bern, Switzerland. |
| |
|
3.00 p.m.
|
Inhaled Gentamicin: Making a Dry Powder Formulation to Satisfy a Clinical Need.
James D. Talton, Ph.D.,
NanoTherapeutics, Alachua, FL. |
| |
|
| 3.30 p.m. |
Inhaled Liposomal Ciprofloxacin: Once a Day Management of Respiratory Infections.
Paul R. Bruinenberg, M.D., Aradigm Corporation, Hayward, CA. |
| |
|
| 4.00 p.m. |
Refreshments |
| |
|
| SESSION 3: |
Identifying Active Transporters that Count! |
| |
|
| |
Sponsor: ‘Our Gold Sponsors’
Moderator: Per Gerde, Ph.D. |
| |
|
| 4.30 p.m. |
Assessing the Role of Transporters in the Disposition of Inhaled Drugs Using a Respiratory Epithelial Cell Culture Model.
Cynthia Bosquillon, Ph.D.,
University of Nottingham, Nottingham, United Kingdom. |
| |
|
| 5.00 p.m. |
Cation Transporters in the Lung: Significance and Implications for Long Acting Cholinergic Drugs.
John Keogh, C.Biol., MSB.,
GlaxoSmithKline, Ware, United Kingdom. |
| |
|
5.00 p.m. -
7.00 p.m. |
Scientific Poster Session & Technology Exhibition |
| |
Sponsor: Copley Scientific
Moderator: Richard N. Dalby, Ph.D. |
|
|
|
|
